Early warning and tracking systems for hypertension-mediated organ damage: a multicenter prospective longitudinal study

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100052065

Enrollment

Unknown

Registered

2021-10-16

Start date

2022-01-01

Completion date

Unknown

Last updated

2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

HMOD(hypertension-mediated organ damage) high-risk group:No

HMOD low-risk group:No

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged >= 18 years; 2. Blood pressure elevation meets at least one of the following: (1) Systolic blood pressure >= 140 mmHg and/or diastolic blood pressure >= 90 mmHg measured in multiple standard clinics; (2) Average of 3-6 days of family self-test using a certified sphygmomanometer systolic blood pressure >= 135 mmHg and/or diastolic blood pressure >= 85 mmHg; (3) Ambulatory blood pressure monitoring 24-hour average blood pressure >= 130/80 mmHg or daytime average blood pressure >= 135/85 mmHg or night blood pressure >= 120/70 mmHg.

Exclusion criteria

Exclusion criteria: 1. History of congestive heart failure, myocardial infarction or coronary revascularization in the past 6 months; 2. Planning percutaneous coronary intervention and coronary artery bypass grafting during screening period; 3. Severe hypertension (SBP >= 180 and /or DBP >= 110 mmHg), secondary hypertension or malignant hypertension; 4. History of stroke, subarachnoid hemorrhage or transient ischemic attack within the last 6 months; 5. Severe valvular heart disease; 6. Congenital heart disease; 7. Severe heart failure (NYHA class IV); 8. Undergoing renal replacement therapy or eGFR <= 30 ml/min/1.73m^2; 9. Diabetes with microalbuminuria or albuminuria; 10. Severe of acute/chronic liver diseases (liver failure, cirrhosis); 11. Pregnant or breastfeeding women; 12. History of malignant tumors; 13. Other serious non-cardiovascular diseases leading to life expectancy of less than 1 year; 14. Severe psychiatric diseases and language disorders; 15. Long-term use of cortisol hormones, sex hormones, immunosuppressants (such as cyclosporine, levamisole), antidepressants, recombinant human erythropoietin, etc. due to comorbidities; 16. Refuse to provide written consent.

Design outcomes

Primary

Measure	Time frame
Blood pressure;Increased left ventricular mass index;New-onset atrial fibrillation;Worsening kidney function;Decline in cognitive function;	—

Countries

China

Contacts

Public ContactHuang Feng

The First Affiliated Hospital of Guangxi Medical University

huangfeng3000@126.com+86 18377150200

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026